User:Mr. Ibrahem/Cobimetinib
Clinical data | |
---|---|
Pronunciation | /ˌkoʊbɪˈmɛtɪnɪb/ KOH-bim-ET-i-nib |
Trade names | Cotellic |
Other names | GDC-0973, XL-518 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615057 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth (tablets)[1] |
Drug class | MEK inhibitor[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | reported from 28%[3] to 46%[1] |
Protein binding | 95%[1] |
Metabolism | Intestinal and low liver clearance (mostly CYP3A4 oxidation and UGT2B7 glucuronidation)[1][3] |
Elimination half-life | 44 hours (mean)[1] |
Excretion | Feces (76–77%), urine (17.9–18%) (after oral and IV administration)[1][4] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C21H21F3IN3O2 |
Molar mass | 531.318 g·mol−1 |
3D model (JSmol) | |
| |
|
Cobimetinib, sold under the brand name Cotellic among others, is a medication used to treat melanoma.[1] Specifically it is used for advanced disease with either BRAF V600E or V600K mutation.[1] It is used together with vemurafenib.[1] Use is not recommended in the United Kingdom.[5] It is taken by mouth.[1]
Common side effects include diarrhea, rash, nausea, fever, sunburns, liver problems, or muscle damage.[2] Other side effects may include bleeding, heart damage, and retinal vein occlusion.[1] Use during pregnancy may harm the baby.[1] It is a MEK inhibitor.[1]
Cobimetinib was approved for medical use in the United States and Europe in 2015.[1][2] In the United Kingdom treatment for 4 weeks costs the NHS about £4,275 as of 2021.[5] This amount in the United States is about 7,300 USD.[6]
References[edit]
- ^ a b c d e f g h i j k l m n o p q r "Cotellic- cobimetinib tablet, film coated". DailyMed. 5 November 2019. Archived from the original on 4 August 2020. Retrieved 19 October 2020.
- ^ a b c d "Cotellic". Archived from the original on 20 January 2021. Retrieved 6 January 2022.
- ^ a b Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, et al. (January 2016). "Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans". Drug Metabolism and Disposition. 44 (1): 28–39. doi:10.1124/dmd.115.066282. PMID 26451002.
- ^ Choo E, Takahashi R, Rooney I, Gates M, Deng A, Musib L (January 30, 2014). "Abstract B160: Assessing Human Absorption, Metabolism, Routes of Excretion and the Contribution of Intestinal Metabolism to the Oral Clearance of Cobimetinib, a MEK Inhibitor". Molecular Cancer Therapeutics. 12 (11 Supplement): B160. doi:10.1158/1535-7163.TARG-13-B160.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1019. ISBN 978-0857114105.
- ^ "Cotellic Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 January 2021. Retrieved 6 January 2022.